Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)
Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The study is conducted to compare safety and efficacy of isoniazid administered as an
adjusted dose based on NAT2 (arylamine N-acetyltransferase type 2)genotype and as a standard
dose.
The hypothesis is that the genotype-adjusted dose is superior to the standard dose with
regard to hepatotoxicity and early treatment failure, respectively, in the group of slow and
rapid acetylators of NAT2.